Reciprocal relationship from CAMP graph: ty fee qualifies for the royalty constraint exception and does not require an estimate of the future transaction price. The Company did not record any license…
Reciprocal relationship from LLY graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from LLY grap…
Reciprocal relationship from SRPT graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from SRPT graph: past several years to further enhance our internal research and development …
Reciprocal relationship from TRDA graph: Reciprocal relationship from BMRN graph: Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and …
Under the Merger Agreement, receipt of the French FDI Clearance satisfies the final condition to the Merger other than conditions that by their nature are to be satisfied at the closing of the Merger.
As of March 31, 2026, and December 31, 2025, the accounts receivable balance for Sanofi included $ 152.6 million and $ 148.0 million, respectively, of unbilled accounts receivable, which becomes paya…
Reciprocal relationship from SPRB graph: mmercial sale. In addition, we will also be entitled to receive a royalty for each unit of non-Company manufactured product sold equal to a range of double-di…
ternal innovation. In April 2026, we acquired Amicus Therapeutics, Inc. (Amicus) to expand and diversify our rare disease product portfolio (the Amicus Acquisition). In addition, in July 2025 we acqu…
Reciprocal relationship from SRPT graph: past several years to further enhance our internal research and development capabilities. However, we currently do not have internal GMP manufacturing capabil…
Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for sub…
BioMarin Pharmaceutical Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BMRN-DEBT
Debt stack $1.4B
90%
Market cache reports total debt of $1.4B.
BMRN-DEBT-8287
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
BioMarin Pharmaceutical Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioMarin Pharmaceutical Inc..
BioMarin Pharmaceutical Inc. Ownership
Holder
Name
Confidence
Evidence
BMRN-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 560 tracked holders.
BioMarin Pharmaceutical Inc. Extended Supply Chain Network
